nbe-002

NBE-002 is a novel antibody-drug conjugate (ADC) designed to target the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is highly expressed in various hematological and solid tumors but minimally present in healthy adult tissues. The drug consists of a humanized recombinant IgG1 monoclonal antibody (huXBR1–402) site-specifically conjugated via a non-cleavable linker to the anthracycline derivative PNU‑159682, using enzymatic sortase A-mediated transpeptidation for precise drug-antibody ratio and product homogeneity. Upon intravenous administration, NBE‑002 binds ROR1 on tumor cells, is internalized, and delivers its cytotoxic payload intracellularly. Its mechanism of action includes DNA intercalation and inhibition of type II DNA topoisomerase, leading to tumor cell death. Preclinical studies have shown direct anti-tumor activity—especially in triple-negative breast cancer—and immune-stimulatory effects such as increased T-cell infiltration into tumors and conversion of "cold" tumors into "hot" ones responsive to checkpoint inhibitors. Developed by NBE-Therapeutics (now part of Boehringer Ingelheim), NBE‑002 has been evaluated primarily for advanced solid tumors including triple-negative breast cancer[1][2][3][4][6][8].

Other names

anti-ROR1/PNU-159682 derivative antibody-drug conjugate